RxDoctor Payments Data

Maria Ilar-Revilla, MD

Internal Medicine · Waipahu, HINPI 1619980471

Payments from drug & device makers

$2,677in general payments, 2019–2025

Across 186 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$751
  • Amarin Pharma, Inc.$690
  • AstraZeneca$386
  • GSK$371
  • Merck$147
  • Sanofi-aventis U.S. LLC$101
  • plus $231 from 6 others

What the payments were for

  • Food & beverage$2,65899%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,677 in reported general payments places this provider in the 80th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$54,611
Medicare patients
106
Services billed
1,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate125$177,514
ProliaDenosumab50$89,144
FarxigaDapagliflozin Propanediol35$56,689
JardianceEmpagliflozin51$53,918
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$18,151
SymbicortBudesonide/Formoterol Fumarate51$18,151
Felodipine ErFelodipine399$13,719
Atorvastatin Calcium952$12,739
Losartan Potassium801$9,897
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$8,096
Lovastatin524$7,450
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$6,790
Amlodipine Besylate519$4,750
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,616
Celecoxib153$3,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$147$177,514125 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$386$92,99197 claims
AmgenProlia$751$89,14450 claims
Boehringer IngelheimJardiance$93$53,91851 claims
PfizerPaxlovid$18$1,30133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Waipahu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →